<DOC>
	<DOCNO>NCT00194038</DOCNO>
	<brief_summary>The purpose research study analyze effectiveness tolerability new medication , aripiprazole ( Abilify ) , individual age 50 year old bipolar disorder ( manic-depressive illness ) .</brief_summary>
	<brief_title>Aripiprazole Late Life Bipolar Disorder</brief_title>
	<detailed_description>While medication valproate ( Depakote others ) lithium generally consider first-line agent late life bipolar disorder , side effect common , many individual bipolar disorder continue symptom spite medication treatment . A continue unmet need availability medication generally well- tolerate effective later life bipolar disorder . Antipsychotic medication Abilify know effective related condition schizophrenia also use physician clinical setting combination mood stabilize medication ( Lithium , Depakote others ) treat symptom bipolar disorder . Currently Abilify approve FDA treat schizophrenia treat bipolar disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Must Bipolar disorder confirm Mini Neuropsychiatric Interview ( MINI ) Must age 50 old Must suboptimal response current psychotropic management include least one following : Behaviors symptoms irritability , agitation , mood liability diminish ability interact others place residence Diminished ability take care basic personal need place residence due symptom bipolar disorder Intolerance current psychotropic medication ; Must live Northeast Ohio area . An unstable medical illness , medical illness , opinion study investigator , likely affect outcome study DSMIV substance dependence ( except nicotine caffeine ) within past 3 month ; Receiving carbamazepine .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Geriatric Psychiatry</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>